AllSight
Companies · NEOG · In Vitro & In Vivo Diagnostic Substances

NEOGEN CORP (NEOG)

NEOGEN CORP (NEOG) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

NEOGEN CORP (NEOG) stock — financials & valuation

Key numbers for NEOGEN CORP (NEOG): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 34/100 — a percentile rank of NEOGEN CORP’s fundamentals against Manufacturing peers, weakest on management. A quality ranking, not a price prediction.

Market cap$2.8B
P / S3.2×
EV / EBITDA36.0×
Gross margin46.9%
Operating margin-2.5%
Net margin-0.9%
Return on equity-0.4%
ROIC-0.7%
Revenue growth-2.7%
Debt / equity0.4×
Dividend yield0.0%

Is NEOGEN CORP overvalued? P/S looks fair vs its 5-year range; EV/EBITDA looks fair vs its 5-year range; P/B looks fair vs its 5-year range.

Independent of the events above — derived from NEOGEN CORP’s own financial statements and shown as context, never as advice.

Aug 7, 2026
Director resignation adds governance uncertainty, with no operational change disclosed
Related companies in In Vitro & In Vivo Diagnostic Substances
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact